Blog

AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease

17 de outubro de 2024 by

in News

Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.

Relacionado

Leave a Reply Cancel reply

Ads Blocker Detected!!!

We have detected that you are using extensions to block ads. Please support us by disabling these ads blocker.

Ads Blocker Detected!!!

We have detected that you are using extensions to block ads. Please support us by disabling these ads blocker.

Refresh

Best Wordpress Adblock Detecting Plugin | CHP Adblock